- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Melphalan, Prednisone, Carfilzomib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 16
- States / cities
- Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 10,738
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Plerixafor
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 8
- States / cities
- Duarte, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
- Conditions
- AML
- Interventions
- Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose, Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose, Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose, Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose, Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose, Ruxolitinib, Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose
- Biological · Drug
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 20
- States / cities
- Duarte, California • La Jolla, California • San Francisco, California + 16 more
- Conditions
- Myelodysplastic Syndromes, Multiple Myeloma, Anemia
- Interventions
- INCB000928
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Miami, Florida • Sarasota, Florida + 5 more
- Conditions
- Acute Blood Loss Anemia, Fracture
- Interventions
- Iron-Dextran Complex Injection [InFed], Saline Placebo
- Drug · Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia, Refractory Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
- Interventions
- Revumenib, Mezigdomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Duarte, California • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
- Conditions
- Leukemia, Lymphoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- estramustine phosphate sodium, paclitaxel, vinorelbine ditartrate
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma, Smoldering, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Interventions
- Omega-3, Curcumin, Probiotic, Whole food, plant-based diet (WFPBD)
- Dietary Supplement · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- CPX-351, Intensive Salvage Therapy
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 31
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 23 more
- Conditions
- Multiple Myeloma
- Interventions
- Survivin Vaccine, Autologous Hematopoietic Cell Transplantation, Prevnar 13, Granulocyte-colony Stimulating Factor
- Biological · Procedure · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric, Adverse Drug Event
- Interventions
- Not listed
- Lead sponsor
- Cipherome, Inc.
- Industry
- Eligibility
- Up to 21 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Multiple Myeloma
- Interventions
- bb2121
- Biological
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 9
- States / cities
- Stanford, California • Bethesda, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Thrombocytopenia, Myocardial Infarction
- Interventions
- Aspirin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Lymphoma
- Interventions
- ixabepilone
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 2
- States / cities
- New York, New York • Burlington, Vermont
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Entospletinib, Daunorubicin, Cytarabine, Decitabine, Azacitidine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Chicago, Illinois • Maywood, Illinois + 10 more
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- azacitidine, lenalidomide
- Drug
- Lead sponsor
- Mikkael Sekeres MD
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Tampa, Florida • Cleveland, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- BI-505
- Biological
- Lead sponsor
- BioInvent International AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Salt Lake City, Utah
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, Waldenström Macroglobulinemia
- Interventions
- panobinostat, everolimus, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Bethesda, Maryland • Rochester, Minnesota
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
- Interventions
- ATV-1601, Placebo
- Drug
- Lead sponsor
- Atavistik Bio, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Augusta, Georgia • Indianapolis, Indiana + 3 more
- Conditions
- Lymphoma, Leukemia, Myeloma
- Interventions
- Resistance Training, Aerobic Exercise, Optional Aerobic Exercise Procedure, Optional In-Person Exercise Sessions
- Behavioral · Radiation
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
- Interventions
- Erythropoietin, Sham Comparator
- Drug · Other
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 24 Hours to 96 Days
- Enrollment
- 318 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2000
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
- Interventions
- GMI-1070, Placebo
- Drug
- Lead sponsor
- GlycoMimetics Incorporated
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Berkeley, California • Sacramento, California + 18 more
- Conditions
- Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS, Fasting, Multiple Myeloma
- Interventions
- Prolonged Fasting Intervention, EDUCATION CONTROL
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sickle Cell Disease
- Interventions
- Interviews and Surveys
- Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee